EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Textbook outcomes among patients undergoing curative resection of pancreatic ductal adenocarcinoma in the era of neoadjuvant therapy

Lingyu Zhu, Zhendong Fu, Xinyu Liu, Bo Li, Xiaohan Shi, Suizhi Gao, Xiaoyi Yin, Huan Wang, Meilong Shi, Penghao Li, Yikai Li, Jiawei Han und 5 weitere

Clinical Surgical Oncology · 2023

DOI: 10.1016/j.cson.2023.100012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Surgical Oncology, 2023. Verfasst von Lingyu Zhu und 16 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neoadjuvant therapy has been the standard care for borderline resectable or locally advanced pancreatic ductal carcinoma (BR/LA PDAC). The textbook outcome (TO) for curative resection after neoadjuvant therapy (NAT) remains understudied. Patients underwent curative resection for PDAC between 2019 and 2020 were confirmed from the multidisciplinary team (MDT) database prospectively maintained by the Department of Pancreatic Hepatobiliary Surgery of Changhai hospital. TO of patients received NAT was compared to those received upfront surgery (UFS), and multivariate analysis of clinicopathological parameters was performed to explore predictors for TO. Of 435 patients, 329(76%) patients received UFS whereas 106(24%) patients received NAT. The TO was 82.1% for the NAT cohort, 77.8% for pancreaticoduodenectomy (PD) and 86.8% for distal pancreatectomy (DP). In the UFS cohort, the TO was 73.3% overall, 70.6% for PD and 77.3% for DP. Patients in the NAT cohort had longer time of operation, more intra-operative blood loss and more vascular resection. However, TO of the NAT cohort were not statistically different compared to that in the UFS cohort (p ​= ​0.27 for PD and p ​= ​0.20 for DP). On multivariable analysis, only diabetes-free was predictive for a better TO rate after PD in the UFS cohort(p ​= ​0.003). There were no factors associated with TO after DP in the UFS cohort, nor after PD or DP in the NAT cohort. As a composite indicator of desired surgical outcome, TO for curative resection after neoadjuvant therapy is similar to that in upfront surgery. All patients with stable or regressed tumors after NAT should be candidates for curative resection in an MDT setting.

Zitieren

APA

Zhu, L., Fu, Z., Liu, X., Li, B., Shi, X., Gao, S., Yin, X., Wang, H., Shi, M., Li, P., Li, Y., Han, J., Ren, Y., Wang, J., Zheng, K., Guo, S., & Jin, G. (2023). Textbook outcomes among patients undergoing curative resection of pancreatic ductal adenocarcinoma in the era of neoadjuvant therapy. Clinical Surgical Oncology. https://doi.org/10.1016/j.cson.2023.100012

Vancouver

Zhu L, Fu Z, Liu X, Li B, Shi X, Gao S, et al. Textbook outcomes among patients undergoing curative resection of pancreatic ductal adenocarcinoma in the era of neoadjuvant therapy. Clinical Surgical Oncology. 2023. doi:10.1016/j.cson.2023.100012

BibTeX
@article{Zhu2023,
  author = {Zhu, Lingyu and Fu, Zhendong and Liu, Xinyu and Li, Bo and Shi, Xiaohan and Gao, Suizhi and Yin, Xiaoyi and Wang, Huan and Shi, Meilong and Li, Penghao and Li, Yikai and Han, Jiawei and Ren, Yiwei and Wang, Jian and Zheng, Kailian and Guo, Shiwei and Jin, Gang},
  title = {Textbook outcomes among patients undergoing curative resection of pancreatic ductal adenocarcinoma in the era of neoadjuvant therapy},
  journal = {Clinical Surgical Oncology},
  year = {2023},
  doi = {10.1016/j.cson.2023.100012}
}
Kostenlos starten →